In laboratories at Georgia State University's Center for Translational Antiviral Research, scientists have just crossed a critical threshold: they've developed GHP-88310, the first once-daily oral antiviral pill designed to fight measles, croup, and other orthoparamyxoviruses that have left patients—especially the most vulnerable—without effective treatment options for far too long.
The breakthrough matters because these viruses are staging a comeback. Measles has resurged across major regions of the United States, Mexico, and Canada in recent months. Meanwhile, human parainfluenzaviruses silently infect roughly 3 million Americans annually, causing life-threatening pneumonia in older adults, immunocompromised individuals, and stem cell transplant recipients—yet no vaccines or therapeutics exist to manage the disease. Until now, doctors facing these infections have had little to offer beyond supportive care.
The research team, led by senior postdoctoral fellow Carolin Lieber and director Richard Plemper, didn't stumble onto this solution by accident. They launched a large high-throughput drug screening campaign, identified a promising early lead, and then refined it through rigorous testing in both rodent and non-rodent animal models and in human airway organoid cultures. The result, published in Science Advances, is a compound that Lieber describes with the confidence of someone who has spent years chasing this goal: "GHP-88310 is the most promising inhibitor of this virus family that we have encountered in years of research."
What makes GHP-88310 genuinely exciting is the combination of three features that rarely come together. The drug is highly potent against a broad spectrum of orthoparamyxoviruses, meaning a single daily dose taken by mouth can tackle multiple threats. It demonstrates excellent tolerability even at very high concentrations in both rodents and higher mammals—a critical safety profile for a medicine intended for vulnerable children and immunocompromised patients. And it has a high barrier against viral escape, meaning the virus is far less likely to evolve resistance to the treatment.
Plemper emphasizes why this safety margin matters so much: "High potency and excellent tolerability ensure a very wide safety margin, which is essential for a drug candidate developed for the treatment of highly vulnerable patient groups and children." These are patients who cannot afford a medicine that might help their viral infection but cause dangerous side effects in the process.
The development of GHP-88310 represents a deliberate shift in how antiviral research can be approached. Rather than waiting for the next pandemic or accepting that certain vulnerable populations simply have no options, Plemper's team designed this drug discovery program from the start with those patient needs front and center. They looked at which viruses posed the greatest threat to which groups, and then built a solution accordingly.
The research has moved from animal models to the threshold of clinical development—though human trials remain ahead. But for the millions of people at risk from these re-emerging orthoparamyxoviruses, and for the health systems trying to protect vulnerable populations, this represents a meaningful turn toward hope: a once-daily pill, taken by mouth, designed specifically for those who need it most.